Abstract:Background The red cell distribution width to albumin ratio (RAR) has emerged as a reliable prognostic marker for mortality in various diseases. However, whether RAR is associated with mortality remains unknown in the general population. Objective Explore whether RAR is associated with all-cause and cause-specific mortality, and to elucidate the dose-response relationship between them. Methods This study included 50622 participants aged 18+ years from US National Health and Nutrition Examination Survey (NHANES), and 418950 participants aged 37+ years from UK Biobank. The potential association between RAR and the risk of all-cause and cause-specific mortality was evaluated by Cox proportional hazard models. Restricted cubic spline regressions were applied to estimate the possible nonlinear relationships. Results NHANES documented 7590 deaths over a median follow-up of 9.4 years, and UK Biobank documented 36793 deaths over a median follow-up of 14.5 years. In multivariable analysis, elevated RAR were significantly associated with a higher risk of all-cause mortality (NHANES: hazard ratio [HR]: 1.86, 95% confidence interval [CI]: 1.81-1.93; UK Biobank: HR: 2.01, 95% CI: 1.96-2.06), as well as mortality due to malignant neoplasms, heart disease, cerebrovascular diseases, respiratory diseases, diabetes mellitus, and others in both the two cohorts (all P-value < 0.05). Conclusions Higher baseline RAR was strongly and independently associated with increased risk of all-cause and cause-specific mortality in the general population. RAR was a promising indicator that simply, reliably, and inexpensively accessible for identifying high-risk of mortality in clinical practice. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement This work was supported by grants from the National Natural Science Foundation of China-Youth Science Fund (82301768, 32300533, 32100510), the Shanghai Sailing Program (23YF1430500), and the Shanghai Rising-Star Program (21QB1400900). ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Data from NHANES are available at [www.cdc.gov/nchs/nhis/index.htm][1], and data from UK Biobank are available on application at [www.ukbiobank.ac.uk/register-apply][2]. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data from NHANES are available at [www.cdc.gov/nchs/nhis/index.htm][1], and data from UK Biobank are available on application at [www.ukbiobank.ac.uk/register-apply][2]. [1]: http://www.cdc.gov/nchs/nhis/index.htm [2]: http://www.ukbiobank.ac.uk/register-apply

Association of Glycated Albumin to Hemoglobin A1c Ratio with All-Cause and Cardiovascular Mortality among US Adults: a Population-Based Cohort Study.

Association Between Glycated Albumin and Adverse Outcomes in Patients with Heart Failure.

L-shaped association between the GA/HbA1c ratio and all-cause mortality in U.S. adults with NAFLD: a cross-sectional study from the NHANES 1999–2004

Relationship of Glycated Hemoglobin A1c with All-Cause and Cardiovascular Mortality among Patients with Hypertension

Relationship between glycated albumin and glycated hemoglobin according to glucose tolerance status: A multicenter study

Associations of Hemoglobin Biomarker Levels of Acrylamide and All-Cause and Cardiovascular Disease Mortality among U.S. Adults: National Health and Nutrition Examination Survey 2003–2006

The U-Shape Relationship Between Glycated Hemoglobin Level and Long-Term All-Cause Mortality Among Patients With Coronary Artery Disease

Glycated Hemoglobin and All-Cause and Cause-Specific Mortality among Adults with and Without Diabetes.

U-shaped association between HbA1c and all-cause mortality in CVD patients with diabetes

Glycated haemoglobin index is a new predictor for all-cause mortality and cardiovascular mortality in the adults

Association between glycated hemoglobin and risk of all‐cause mortality in community patients with type 2 diabetes: A prospective cohort study

Association of Hemoglobin Glycation Index and Glycation Gap with Cardiovascular Disease among US Adults

Elevated Glycated Albumin in Serum Is Associated with Adverse Cardiac Outcomes in Patients with Acute Coronary Syndrome Who Underwent Revascularization Therapy

Association of haemoglobin glycation index with all-cause and cardiovascular disease mortality in diabetic kidney disease: a cohort study

Hemoglobin A1c and long-term mortality in patients undergoing coronary angiography: the ECAD registry

Association of Glycation Gap with All-Cause and Cardiovascular Mortality in US Adults: A Nationwide Cohort Study

Serum and Tissue Levels of Advanced Glycation End Products and Risk of Mortality in Patients on Maintenance Hemodialysis

Association Between Body Mass Index Combined with Albumin: Creatinine Ratio and All-cause Mortality in Chinese Population.

Association of Red Cell Distribution Width to Albumin Ratio with Risk of All-Cause and Cause-Specific Mortality: Two Prospective Cohort Studies

Association of glycated hemoglobin A1c levels with cardiovascular outcomes in the general population: results from the BiomarCaRE (Biomarker for Cardiovascular Risk Assessment in Europe) consortium

Association of the hemoglobin glycation index with cardiovascular and all-cause mortality in individuals with hypertension: findings from NHANES 1999–2018